

## SynTech research, ObjetBio join forces to bring novel microbial solutions to global markets

16 June 2026 | News

**This collaboration highlights the strong commercial potential of ObjetBio's technology and SynTech's global capabilities in testing and regulatory support**



**This collaboration highlights the strong commercial potential of ObjetBio's technology and SynTech's global capabilities in testing and regulatory support**

SynTech Research Group, a leading global agricultural CRO, and ObjetBio, a South Korean agricultural biotechnology company, signed a Memorandum of Understanding to advance the global validation, regulatory readiness, and commercialisation of ObjetBio's proprietary microbial-metabolite technology. This collaboration highlights the strong commercial potential of ObjetBio's technology and SynTech's global capabilities in testing, regulatory support, and market entry enablement.

The signing took place at SynTech Research's Spanish headquarters in Picanya, Valencia. Vice-President Hoon Choi, on behalf of ObjetBio, and Dr Maris  Borja, Global Regulatory Affairs Lead at SynTech Research Group, signed the agreement outlining the scope of the partnership. Following the signing, the two teams held a project meeting and toured SynTech's facilities, including the ecotoxicology and microbiology laboratories, as well as the greenhouses and phenotyping station.

The next stop on the tour was the Canary Islands, where SynTech conducts GLP-standard trials, including efficacy testing and post-harvest simulations to support product development and regulatory requirements. ObjetBio also visited SynTech Research Group's global headquarters in La Chapelle de Guinchay, France, where the company conducts field research and operates its ecotoxicology laboratory, followed by a visit to SynTech's analytical laboratory in Lyon.

"We are looking forward to a long-lasting and productive partnership with ObjetBio, supporting their research and regulatory needs," said Dr Maris  Borja, Global Regulatory Affairs Lead at SynTech Research Group.

“Our collaboration with SynTech Research Group reflects the strong global potential of ObjetBio’s technology platform. We look forward to leveraging SynTech’s capabilities to accelerate validation, regulatory alignment, and commercialisation,” added In-Seong Kim, CEO of ObjetBio.